Sandstone Diagnostics, Inc. — Department of Health and Human Services SBIR Phase I: DESCRIPTION (provided by applicant): The proposed Phase I SBIR project will support Sandst
Sandstone Diagnostics, Inc. — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $149,189
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Solicitation
- PA13-234
- NAICS
- —
- Place of performance
- CA
- Period
- —
Description
DESCRIPTION (provided by applicant): The proposed Phase I SBIR project will support Sandstone Diagnostics, Inc. to demonstrate feasibility of a commercial point-of-care diagnostic system for rapid detection of trace toxin levels from clinical samples. Significance: Early clinica detection of intoxication is critical for improved prognosis in cases of suspected exposure to NIAID priority toxins. Existing clinical diagnostic approaches are inadequate, and there remain no FDA-cleared tests for many priority toxins due to the extreme analytical sensitivities required for confirmation of intoxication from clinical samples (e.g. whole blood). Innovation: Our patent-pending system uniquely addresses this need with rapid (~15 minute) and multiplexed quantitation ofNIAID priority toxins directly from clinical samples with no upfront sample preparation. Assays developed to date include Botulinum Neurotoxin, Shiga-like toxin, Ricin, Staphylococcal Enterotoxin B, and Anthrax. We have proven that the system achieves